Atossa Therapeutics (ATOS) Return on Capital Employed (2012 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Return on Capital Employed of 112.11% for Q1 2026, down 7096.0% year-over-year from 1.6% in Q1 2025, and down 34.49% quarter-over-quarter from 83.36% in Q4 2025.
Atossa Therapeutics (ATOS) Return on Capital Employed (2012 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Return on Capital Employed for 14 consecutive years, with 112.11% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 7096.0% year-over-year to 112.11%; the TTM figure through Mar 2026 stood at 112.11% (down 7096.0% YoY), while the FY2025 annual figure was 69.07%, down 3513.0% from the prior year.
- Return on Capital Employed declined to 112.11% in Q1 2026 per ATOS's latest filing, from 83.36% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 15.86% in Q1 2022 and bottomed at 112.11% in Q1 2026.
- Historically, Return on Capital Employed has averaged 40.51% across 5 years, with a median of 35.39% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 92 bps — and 2026, when it tumbled 7096 bps.
- Atossa Therapeutics' Return on Capital Employed stood at 23.16% in 2022, then tumbled by 45 bps to 33.47% in 2023, then slipped by 13 bps to 37.84% in 2024, then sank by 120 bps to 83.36% in 2025, then tumbled by 34 bps to 112.11% in 2026.
- Business Quant data shows ATOS's Return on Capital Employed at 112.11% in Q1 2026, 83.36% in Q4 2025, and 61.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Atossa Therapeutics | 22.79 Mn | 22.79 Mn | - | -132.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -132.33% |
| Mar 31, 2026 | -112.11% |
| Dec 31, 2025 | -83.36% |
| Sep 30, 2025 | -61.95% |
| Jun 30, 2025 | -49.32% |
| Mar 31, 2025 | -41.15% |
| Dec 31, 2024 | -37.84% |
| Sep 30, 2024 | -38.36% |
| Jun 30, 2024 | -36.93% |
| Mar 31, 2024 | -35.39% |
| Dec 31, 2023 | -33.47% |
| Sep 30, 2023 | -30.02% |
| Jun 30, 2023 | -28.71% |
| Mar 31, 2023 | -25.69% |
| Dec 31, 2022 | -23.16% |
| Sep 30, 2022 | -19.11% |
| Jun 30, 2022 | -16.16% |
| Mar 31, 2022 | -15.86% |
| Dec 31, 2021 | -14.76% |
| Sep 30, 2021 | -13.95% |